Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)

China · Delayed Price · Currency is CNY

6.74

+0.31 (4.82%)

Oct 23, 2026, 3:00 PM CST

Market Cap	4.74B +16.0%
Revenue (ttm)	400.80M -0.4%
Net Income	-126.91M
EPS	-0.18
Shares Out	703.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,897,193
Open	6.30
Previous Close	6.43
Day's Range	5.88 - 6.88
52-Week Range	4.01 - 8.40
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2026

About SHA:603669

Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Pharmaceutical Group Co.,Ltd. was founded in 2003 and is based in Shannan, China. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2003

Employees 284

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603669

Full Company Profile

Financial Performance

In 2025, SHA:603669's revenue was 322.48 million, a decrease of -15.09% compared to the previous year's 379.78 million. Losses were -193.24 million, 47.8% more than in 2024.

Financial Statements